Malander Susanne, Rambech Eva, Kristoffersson Ulf, Halvarsson Britta, Ridderheim Mona, Borg Ake, Nilbert Mef
Department of Oncology, Institute of Clinical Sciences, Lund University Hospital, SE-221 85 Lund, Sweden.
Gynecol Oncol. 2006 May;101(2):238-43. doi: 10.1016/j.ygyno.2005.10.029. Epub 2005 Dec 19.
Ovarian cancer has one of the highest fractions of hereditary cases. The hereditary breast and ovarian cancer syndrome, primarily due to mutations in BRCA1 and BRCA2, is the main cause of heredity, but also the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome confers an increased risk of ovarian cancer. In order to clarify the contribution of HNPCC to the development of ovarian cancer, we collected data on family history of cancer and characterized MMR function in a consecutive series of 128 tumors unselected for age at diagnosis and previously characterized for BRCA gene mutations.
Expression of the MMR proteins MLH1, PMS2, MSH2, and MSH6 was analyzed by immunohistochemistry using tissue microarray sections. Tumors with reduced staining or loss of staining were also analyzed for microsatellite instability (MSI).
Loss of MMR protein expression was identified in 3 ovarian cancers, all of which had a MSI-high phenotype. DNA sequence analysis revealed disease-causing germline mutations (deletions of exons 4-6 in MLH1 and a 1-nucleotide deletion in exon 5 of MSH6) in two patients diagnosed at ages 40 and 49 years, both of whom had family histories suggestive of HNPCC. The genetic defect in the third case, which was a 47-year old woman without knowledge about her family history with loss of MLH1/PMS2 expression in the tumor tissue, remains elusive. A family history suggestive of HNPCC was identified in an additional case, but this tumor showed normal, retained MMR protein expression and a microsatellite stable phenotype.
About 2% of ovarian cancer is caused by germline mutations in the MMR-genes, a minor proportion as compared to the contribution of the BRCA-genes (11% in the present series). However, identification of HNPCC patients is important since it allows inclusion of high-risk individuals into control programs aimed at preventing the more frequent colorectal and endometrial cancers. Tumors within the HNPCC-spectrum should therefore be included when recording a family history of cancer among patients diagnosed with ovarian cancer.
卵巢癌是遗传性病例比例最高的癌症之一。遗传性乳腺癌和卵巢癌综合征主要是由于BRCA1和BRCA2基因的突变,是遗传的主要原因,但遗传性非息肉病性结直肠癌(HNPCC)综合征也会增加患卵巢癌的风险。为了阐明HNPCC对卵巢癌发生发展的影响,我们收集了癌症家族史数据,并对128例连续的肿瘤进行了错配修复(MMR)功能特征分析,这些肿瘤未按诊断年龄进行选择,且之前已对BRCA基因突变进行了特征分析。
使用组织微阵列切片通过免疫组织化学分析MMR蛋白MLH1、PMS2、MSH2和MSH6的表达。对染色减少或染色缺失的肿瘤也进行微卫星不稳定性(MSI)分析。
在3例卵巢癌中发现了MMR蛋白表达缺失,所有这些肿瘤均具有高微卫星不稳定性(MSI-H)表型。DNA序列分析显示,两名分别在40岁和49岁确诊的患者存在致病的种系突变(MLH1基因外显子4-6缺失,MSH6基因外显子5缺失1个核苷酸),这两名患者均有提示HNPCC的家族史。第三例患者为一名47岁女性,其家族史不详,肿瘤组织中MLH1/PMS2表达缺失,其基因缺陷仍不清楚。在另外一例中发现了提示HNPCC的家族史,但该肿瘤显示MMR蛋白表达正常且保留,微卫星稳定表型。
约2%的卵巢癌是由MMR基因的种系突变引起的,与BRCA基因的影响(本系列中为11%)相比,这一比例较小。然而,识别HNPCC患者很重要,因为这可以将高危个体纳入旨在预防更常见的结直肠癌和子宫内膜癌的控制项目。因此,在记录卵巢癌患者的癌症家族史时,应纳入HNPCC谱系内的肿瘤。